Categories Earnings, Technology

Pareteum beats Q1 estimates, raises full-year guidance

Pareteum Corporation (NASDAQ: TEUM) surpassed analysts’ expectations on revenue and earnings for the first quarter of 2019, sending the stock climbing 2.8% in aftermarket hours on Tuesday.

Total revenues jumped 460% year-over-year to $23 million. The net dollar-based expansion rate represented 144% growth.

Net loss was $5.7 million, or $0.06 per basic share, compared to $2.1 million, or $0.04 per basic share, in the prior-year quarter. Adjusted EPS was $0.02.

Pareteum reports first quarter 2019 results

Hal Turner, Pareteum’s Founder, Executive Chairman and Principal Executive Officer stated, “We are very pleased with our strong first quarter results, delivering 460% revenue growth in Q1 2019 compared to Q1 2018. Pareteum’s core business, pre-acquisitions, has grown 33% over the prior quarter. We are proud of the significant business transformation we have achieved over the past few years. Pareteum is a fast-growing and profitable SaaS and communications service provider. Our software and platform solutions are unique in the market, our global TEUM is executing, we are well positioned to capture the large market opportunity, and we are committed to our mission to connect every person and every(thing).”

The company’s 36-month contractual revenue backlog rose to $938 million, up from $200 million in the prior-year period with a conversion rate to revenue of 101%. Connections increased 441% to 12,012,000.

Pareteum raised its guidance for the full year of 2019. The company now expects revenue to grow 255-285% year-over-year to a range of between $115 million and $125 million.

 

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top